|Bid||1.100 x 100|
|Ask||1.540 x 200|
|Day's range||1.110 - 1.190|
|52-week range||0.930 - 1.470|
|PE ratio (TTM)||3.47|
|Earnings date||2 Aug 2017 - 7 Aug 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||2.15|
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
VIVUS, Inc. announced today that it has entered into a settlement agreement with Actavis Laboratories FL resolving patent litigation related to Qsymia® capsules CIV. The litigation, which has been pending ...
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).